← Leaderboards
Alexander H. Stegh
Dana-Farber Cancer Inst
$12,620,634
Attributed
$14,579,352
Total exposure
9
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.9M · FY2007–25$5M$3.8M$2.5M$1.3M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,579,352 · 9
By mechanism
R01$8,448,774 · 4
U54$3,717,501 · 2
P50$1,493,547 · 1
R00$739,530 · 1
K99$180,000 · 1
Top collaborators
- Chad A. Mirkin6 shared
- Daniel R Wahl2 shared
Most similar at Dana-Farber Cancer Inst
Same institution · by research overlap
- Tracy T Batchelor$27,819,477
- Hui Feng$3,909,226
- Julie-Aurore Losman$3,002,683
- Franziska Michor$16,040,992
- Diana Shi$1,011,306
Others in their field
Top investigators on “Glioma”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$158,144,386
- Todd A Alonzo · University Of Colorado Denver/Hsc Denver$72,436,447
- David Heimbrook · Leidos Biomedical Research, Inc.$56,561,099
- Gregory H Reaman · National Childhood Cancer Foundation$49,046,612
- Melissa L Bondy · Stanford University$36,047,564
- Brad H. Pollock · University Of Florida$28,646,726
Research focus
GliomaCellsTumorGlioblastomaMalignant GliomaIn VivoResistanceMediatingApoptosisUptakeBaseProteinsRna InterferenceMouse ModelDiagnosisMolecularNeoplastic CellGeneticSmall Interfering RnaToxic EffectXenograft ProcedureGrowthIn VitroModality
Grant awards (35)
Targeting Myeloid Metabolism to Reprogram the Tumor Microenvironment of Glioblastoma$2,467,799
R01 · FY2025 · CA · contact PI
Spherical Nucleic Acid nano-architectures as first-in-class cGAS agonists for the immunotherapeutic treatment of Glioblastoma.$943,101
R01 · FY2025 · CA · contact PI
Inhibition of wild-type IDH1 as a ferroptosis-inducing therapeutic approach for the treatment of malignant glioma.$480,412
R01 · FY2025 · NS · contact PI
Inhibition of wild-type IDH1 as a ferroptosis-inducing therapeutic approach for the treatment of malignant glioma.$474,236
R01 · FY2024 · NS · contact PI
Spherical Nucleic Acid nano-architectures as first-in-class cGAS agonists for the immunotherapeutic treatment of Glioblastoma.$444,533
R01 · FY2024 · CA · contact PI
Inhibition of wild-type IDH1 as a ferroptosis-inducing therapeutic approach for the treatment of malignant glioma.$499,261
R01 · FY2023 · NS · contact PI
Spherical Nucleic Acid nano-architectures as first-in-class cGAS agonists for the immunotherapeutic treatment of Glioblastoma.$425,597
R01 · FY2023 · CA · contact PI
Inhibition of wild-type IDH1 as a ferroptosis-inducing therapeutic approach for the treatment of malignant glioma.$498,788
R01 · FY2022 · NS · contact PI
Spherical Nucleic Acid nano-architectures as first-in-class cGAS agonists for the immunotherapeutic treatment of Glioblastoma.$443,482
R01 · FY2022 · CA · contact PI
Project 3: Using RNAi-based Spherical Nucleic Acid (SNA) Nanoconjugates Targeting Bcl2L12 to Promote Therapy-Induced Apoptosis in Glioblastoma$293,282
P50 · FY2022 · CA · contact PI
Systemic RNA interference to reactivate p53 tumor suppression$352,899
R01 · FY2021 · CA · contact PI
Project 3: Using RNAi-based Spherical Nucleic Acid (SNA) Nanoconjugates Targeting Bcl2L12 to Promote Therapy-Induced Apoptosis in Glioblastoma$262,751
P50 · FY2021 · CA · contact PI
Systemic RNA interference to reactivate p53 tumor suppression$353,176
R01 · FY2020 · CA · contact PI
Project 3: Using RNAi-based Spherical Nucleic Acid (SNA) Nanoconjugates Targeting Bcl2L12 to Promote Therapy-Induced Apoptosis in Glioblastoma$347,798
P50 · FY2020 · CA · contact PI
Project 2: Spherical Nucleic Acids for Metabolic Reprogramming of Malignant Glioma$568,078
U54 · FY2019 · CA · contact PI
Systemic RNA interference to reactivate p53 tumor suppression$343,370
R01 · FY2019 · CA · contact PI
Project 3: Using RNAi-based Spherical Nucleic Acid (SNA) Nanoconjugates Targeting Bcl2L12 to Promote Therapy-Induced Apoptosis in Glioblastoma$334,161
P50 · FY2019 · CA · contact PI
Project 2: Spherical Nucleic Acids for Metabolic Reprogramming of Malignant Glioma$589,044
U54 · FY2018 · CA · contact PI
Systemic RNA interference to reactivate p53 tumor suppression$361,766
R01 · FY2018 · CA · contact PI
Project 3: Using RNAi-based Spherical Nucleic Acid (SNA) Nanoconjugates Targeting Bcl2L12 to Promote Therapy-Induced Apoptosis in Glioblastoma$255,555
P50 · FY2018 · CA · contact PI
Project 2: Spherical Nucleic Acids for Metabolic Reprogramming of Malignant Glioma$530,118
U54 · FY2017 · CA · contact PI
Systemic RNA interference to reactivate p53 tumor suppression$360,354
R01 · FY2017 · CA · contact PI
Project 2: Spherical Nucleic Acids for Metabolic Reprogramming of Malignant Glioma$553,996
U54 · FY2016 · CA · contact PI
Project 2: Spherical Nucleic Acids for Metabolic Reprogramming of Malignant Glioma$533,233
U54 · FY2015 · CA · contact PI
Preclinical Validation of Polyvalent siRNA Gold Nanoparticle Conjugates as anti-G$169,408
U54 · FY2014 · CA · contact PI
Preclinical Validation of Polyvalent siRNA Gold Nanoparticle Conjugates as anti-G$160,627
U54 · FY2013 · CA · contact PI
Preclinical Validation of Polyvalent siRNA Gold Nanoparticle Conjugates as anti-G$5,398
U54 · FY2013 · CA · contact PI
Preclinical Validation of Polyvalent siRNA Gold Nanoparticle Conjugates as anti-G$209,018
U54 · FY2012 · CA · contact PI
The Role of Bcl2L12 in the Genesis of Malignant Glioma$241,530
R00 · FY2011 · CA · contact PI
Preclinical Validation of Polyvalent siRNA Gold Nanoparticle Conjugates as anti-G$184,314
U54 · FY2011 · CA · contact PI
The Role of Bcl2L12 in the Genesis of Malignant Glioma$249,000
R00 · FY2010 · CA · contact PI
Preclinical Validation of Polyvalent siRNA Gold Nanoparticle Conjugates as anti-G$214,267
U54 · FY2010 · CA · contact PI
The Role of Bcl2L12 in the Genesis of Malignant Glioma$249,000
R00 · FY2009 · CA · contact PI
The Role of Bcl2L12 in the Genesis of Malignant Glioma$90,000
K99 · FY2008 · CA · contact PI
The Role of Bcl2L12 in the Genesis of Malignant Glioma$90,000
K99 · FY2007 · CA · contact PI